No price history available.
Key financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | THBm | 2,601 | 2,987 | 4,107 | 4,202 | 4,635 | 5,277 | N/A | N/A |
| Operating profit | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | THBm | 202 | 249 | 568 | 558 | 713 | 823 | N/A | N/A |
| EPS reported | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Praram 9 Hospital Public Company Limited manages Praram 9 Hospital, a prominent medical institution located in Thailand. This facility delivers a broad spectrum of tertiary healthcare services, encompassing health promotion, preventative medicine, thorough diagnosis, effective treatment, and comprehensive rehabilitation. Its core medical specialties include obstetrics and gynecology, general surgery, internal medicine, pediatrics, advanced kidney transplantation, cardiovascular care, and orthopedics. The hospital further distinguishes itself with numerous specialized centers, addressing areas such as diabetes and metabolic conditions, gastroenterology and hepatobiliary issues, neurological disorders, routine health check-ups, urgent care, physical therapy and rehabilitation, advanced imaging (radiology), ophthalmology, otolaryngology (ear, nose, and throat), dentistry, mental well-being, dermatology and cosmetic procedures, breast health, joint care, spinal conditions, allergy management, oncology, sleep disorders, pulmonary and respiratory diseases, wellness programs, and LASIK eye surgery. Established in 1992, the company maintains its primary base of operations in Bangkok, Thailand.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Praram 9 Hospital Public Company Limited (PR9.BK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Praram 9 Hospital Public Company Limited manages Praram 9 Hospital, a prominent medical institution located in Thailand. This facility delivers a broad spectrum of tertiary healthcare services, encompassing health promotion, preventative medicine, thorough diagnosis, effective treatment, and comprehensive rehabilitation. Its core medical specialties include obstetrics and gynecology, general surgery, internal medicine, pediatrics, advanced kidney transplantation, cardiovascular care, and orthopedics. The hospital further distinguishes itself with numerous specialized centers, addressing areas such as diabetes and metabolic conditions, gastroenterology and hepatobiliary issues, neurological disorders, routine health check-ups, urgent care, physical therapy and rehabilitation, advanced imaging (radiology), ophthalmology, otolaryngology (ear, nose, and throat), dentistry, mental well-being, dermatology and cosmetic procedures, breast health, joint care, spinal conditions, allergy management, oncology, sleep disorders, pulmonary and respiratory diseases, wellness programs, and LASIK eye surgery. Established in 1992, the company maintains its primary base of operations in Bangkok, Thailand.